article thumbnail

Event Summary – Masterclass: International Pharma Marketing by Shailesh Kapadia

PharmaState Academy

Discussions also covered the hierarchy in international marketing, expected packages, responsibilities, and territories of medical representatives and country managers. He highlighted potential opportunities due to the low cost of skilled labor, expanding market size, and increasing global demand for generic drugs.

article thumbnail

Essential elements of a strong, global medicines supply chain

Quality Matters

FDA are co-hosting the APEC Medical Product Supply Chain Dialogue as a signature event of the U.S. In my keynote remarks, I highlighted the following elements of a strong medicines supply chain. in a platform that assesses the vulnerability of specific medicines to supply chain disruptions. To advance this goal, USP and the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What happened to all the antibiotics?

pharmaphorum

A spokesperson for the agency stated, “Shortages can have multiple causes, including manufacturing problems causing delays or interruption in the production, shortages of raw materials, increased demand of medicines, distribution problems, labour disruptions, and natural disasters.”

article thumbnail

Why are clinical trials struggling with diversity?

pharmaphorum

Factors such as ethnicity, gender, sexual orientation and age can contribute to interindividual differences in treatment responses and risks of adverse events. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines. About the authors.

Packaging 138
article thumbnail

Halting Europe’s essential medicines manufacturing exodus

European Pharmaceutical Review

This reliance on sourcing API from other nations puts Europe’s entire manufacturing cycle at risk, especially in the event of global crises and geopolitical tensions. This is likely to make some essential medicines and APIs economically unsustainable to manufacture.